Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092013 | 0.87 | KCNH2 (0.46) | TAAR1KCNH2GPR84L3MBTL1IDO1 | |
| SCHEMBL715204 | 0.85 | KCNH2 (0.41) | TAAR1KCNH2CYP2A6 | |
| SCHEMBL258549 | 0.79 | TSHR (0.32) | TAAR1 | |
| SCHEMBL216731 | 0.78 | — | — | |
| SCHEMBL7664369 | 0.78 | NPC1 (0.37) | TAAR1PTGS2 | |
| SCHEMBL819968 | 0.76 | SKP2 (0.35) | KCNH2 | |
| SCHEMBL815744 | 0.74 | KCNH2 (0.40) | KCNH2TP53GPR84L3MBTL1PTGS1 | |
| SCHEMBL8478011 | 0.73 | TDP1 (0.33) | — | |
| SCHEMBL984972 | 0.73 | KCNH2 (0.43) | KCNH2TP53GPR84L3MBTL1PTGS1 | |
| SCHEMBL980143 | 0.73 | KCNH2 (0.43) | KCNH2TP53GPR84L3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395730-B1 | CARDIOVASCULAR DISORDERS | ICAGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6174908-B1 | TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE | ICAGEN, INC. | 2001-01-16 | — | — | US | disclosed |